Chongqing University and enterprise research and development of super bacterial vaccine obtained clinical approval; humanwell pharmaceutical indirectly participated in research and development enterprises

The recombinant Staphylococcus aureus vaccine, developed by the Third Military Medical University and Chongqing Yuanlun Biotechnology Co., Ltd jointly by the University and the enterprise, has been approved by the clinical trial of the State Food and Drug Administration and officially entered the human clinical research stage The source of this news comes from the report of Chongqing special telegram of people's network (603000) on July 22 It is worth noting that Chongqing Yuanlun Biotechnology Co., Ltd mentioned above also hides a number of biological enterprises, most of which indirectly hold the company According to the industrial and commercial data of Chongqing Yuanlun Biotechnology Co., Ltd., on June 15 this year, the equity structure of the company was changed to sole proprietorship of legal person, and the shareholder was Chengdu OULIN Biotechnology Co., Ltd Chengdu OULIN Biotechnology Co., Ltd was founded in 2009, and is also a vaccine manufacturer The company's newly changed investment proportion on April 29 this year shows that the shareholders are composed of five natural persons and five legal persons According to the industrial and commercial registration data, among the five legal person investors, Fuxin and bio Pharmaceutical (399441) Co., Ltd from Wuhan accounted for 9.1% of the company's investment The results show that Fuxin and bio Pharmaceutical (399441) Co., Ltd are the holding subsidiaries of the listed company humanwell Pharmaceutical (600079) Today's Chongqing media reported that the vaccine is the first "super bacteria" vaccine independently developed and carried out human clinical research in our army, and also the most antigen containing Staphylococcus aureus vaccine in the world.